Hemab Therapeutics Holdings, Inc.

COAG Nasdaq SEC CIK 2114044
Follow Hemab Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$27.3M −60% vs same quarter last year
EPS, diluted −$0.58 +96.8% vs same quarter last year
Operating cash flow −$28.3M −72.6% vs same quarter last year
Operating income −$29.8M −74.5% vs same quarter last year
Net income by quarter
−$15.3M
−$12.2M
−$17.1M
−$22.7M
−$24.2M
−$27.3M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing